Taiwanese firm CancerFree Biotech Ltd. has developed a breakthrough for patients with stage 2 solid tumor. Stage 2 patients or above shortens the drug therapy selection process through a personalized cancer profile, the innovative technology will be showcasing at US Bio 2022. ...